Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson's Disease

BETHESDA, Md., May 03, 2023 -- Gain Therapeutics, Inc. , a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced that Innosuisse, the... | May 3, 2023

Related Keywords

Switzerland ,Swiss ,Matthias Alder ,Nasdaq ,Swiss Innovation Agency ,Company Swiss Accelerator ,Gain Therapeutics Inc ,Michaelj Fox Foundation For Parkinson Research ,Company Annual Report On Form ,Silverstein Foundation For Parkinson ,Exchange Commission ,Swiss Accelerator ,Structurally Targeted Allosteric Regulators ,Chief Executive Officer ,Manolo Bellotto ,Chief Strategy Officer ,General Manager ,Gain Therapeutics ,Silverstein Foundation ,Private Securities Litigation Reform Act ,Financial Condition ,Annual Report ,Quarterly Reports ,Media Contact ,Nc Stock Exchange ,News ,Information ,Press Release ,Bay ,023 ,Rain ,Biotechnology ,Company ,Reading ,The ,Discovery ,End ,Development ,F ,Llosteric ,Mall ,Olecule ,Oday ,Nnounced ,Hat Ganx Us36269b1052 ,